Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $9.5 million.

  • Cytosorbents' Operating Expenses fell 553.24% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year decrease of 1307.4%. This contributed to the annual value of $41.9 million for FY2024, which is 2224.4% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Operating Expenses is $9.5 million, which was down 553.24% from $10.4 million recorded in Q2 2025.
  • Cytosorbents' 5-year Operating Expenses high stood at $17.2 million for Q4 2021, and its period low was $9.5 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $12.3 million, with a median of $12.6 million in 2022.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 4465.99% in 2021, then plummeted by 3018.67% in 2024.
  • Quarter analysis of 5 years shows Cytosorbents' Operating Expenses stood at $17.2 million in 2021, then dropped by 29.66% to $12.1 million in 2022, then grew by 20.88% to $14.6 million in 2023, then plummeted by 30.19% to $10.2 million in 2024, then dropped by 6.8% to $9.5 million in 2025.
  • Its Operating Expenses was $9.5 million in Q3 2025, compared to $10.4 million in Q2 2025 and $10.1 million in Q1 2025.